Amgen Inc. (AMGN) To Go Ex-Dividend on November 20th

Amgen Inc. (NASDAQ:AMGN – Get Free Report) announced a quarterly dividend on Tuesday, October 27th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share by the medical research company on Friday, December 11th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th.

Amgen has raised its dividend by an average of 0.1% per year over the last three years and has increased its dividend every year for the last 14 years. Amgen has a payout ratio of 46.8% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Amgen to earn $25.04 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 40.3%.

Amgen Trading Down 0.9%

Shares of AMGN stock opened at $457.93 on Wednesday. The business has a 50-day moving average of $427.10 and a 200 day moving average of $382.34. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen has a 1-year low of $312.39 and a 1-year high of $483.99. The stock has a market capitalization of $247.70 billion, a PE ratio of 26.56, a P/E/G ratio of 3.22 and a beta of 0.43.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. During the same quarter last year, the business earned $5.64 earnings per share. The business’s revenue was up 8.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Amgen will post 23.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. HSBC downgraded shares of Amgen from a “buy” rating to a “hold” rating and lowered their price objective for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. Morgan Stanley raised their target price on Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 4th. Citigroup raised their target price on Amgen from $405.00 to $465.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. Robert W. Baird boosted their price target on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group upped their price target on Amgen from $384.00 to $440.00 and gave the company a “hold” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus target price of $425.69.

View Our Latest Report on AMGN

Amgen Company Profile

(Get Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Further Reading

Dividend History for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.